{
  "abstract": "We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. Investigations excluded infectious causes, and flexible sigmoidoscopy with biopsy demonstrated lymphocytic colitis. His symptoms persisted despite discontinuation of Braftovi-Mektovi (BRAF–MEK) therapy and required escalation of corticosteroid therapy and budesonide initiation. This case highlights the diagnostic challenges of differentiating ICI-mediated colitis from adverse events of targeted therapy and underscores the importance of endoscopic and histological confirmation in guiding treatment.",
  "authors": [
    {
      "affiliations": [
        "Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"
      ],
      "name": "Reem Matar"
    },
    {
      "affiliations": [
        "Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"
      ],
      "name": "Khalid Abu Zeinah"
    },
    {
      "affiliations": [
        "Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"
      ],
      "name": "Tanish Modi"
    },
    {
      "affiliations": [
        "Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"
      ],
      "name": "Allison Ducharme-Smith"
    }
  ],
  "title": "Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma",
  "uid": "8ac6af9e-8cab-5ca9-9b26-e0e90812a81c"
}